Monday, May 23, 2022 3:14:18 PM
The scientific discussion of primary endpoints is not a formal TLD release by the company. And the importance is not just a full TLD, more importantly, I believe it marks the start of many upcoming news events and catalysts.
On building credibility and relationship with journalists, I think being in a quiet period does not mean a lack of relationship. Instead fewer words when nothing can be said is a form of respect. And delivering actual results and proof of significant long tail surviving patients earns is the ultimate form of credibility to all parties (patients, oncologists, journalists, and readership).
To the underlying question of a low stock price, VikingInvest's post should provide some comfort to rattled retail shareholders and to those that panic-sold and thinking of buying back. NWBO communications had their hands tied behind their backs because they have been operating under a smart stealth mode and because they are surrounded by a pack of wolves. Well folks, their hands are about to be untied.
On building credibility and relationship with journalists, I think being in a quiet period does not mean a lack of relationship. Instead fewer words when nothing can be said is a form of respect. And delivering actual results and proof of significant long tail surviving patients earns is the ultimate form of credibility to all parties (patients, oncologists, journalists, and readership).
To the underlying question of a low stock price, VikingInvest's post should provide some comfort to rattled retail shareholders and to those that panic-sold and thinking of buying back. NWBO communications had their hands tied behind their backs because they have been operating under a smart stealth mode and because they are surrounded by a pack of wolves. Well folks, their hands are about to be untied.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
